| Purpose:To observe the clinical efficacy and safety of the treatment of anti- tumor mixture in the treatment of primary hepatocellular carcinoma(HCC), and to explore an effective method for the treatment of advanced hepatocellular carcinoma. The malignant degree of primary liver cancer is high, and it is easy to occur invasion and metastasis. It is a high incidence of cancer, high mortality and poor prognosis. The experience of Professor Shen Zhongyuan in the Department of liver diseases of Hubei Provincial Traditional Chinese Medical Hospital was confirmed by the observation of the clinical efficacy of 24 patients with advanced liver cancer.Method:Selected 48 patients were collected in Hubei Province Hospital of traditional Chinese medicine liver disease center outpatient and ward, in line with the liver cancer diagnostic criteria and TCM syndrome of stagnation of liver qi and spleen deficiency and qi stagnation and blood stasis and phlegm, divided into treatment group and control group, 24 cases of the treatment group and the control group(n = 24). The two groups were given diet, the treatment group received Fuzheng anticancer composition, daily a agent, 200 ml each time, twice a day service, treatment for 3 months, control group was given Fufang Banmao capsule, a 2 capsules, 3 times a day, 1 month for a course of treatment, continuous observation of three courses.In the course of treatment every 3 months, the CT level, serum AFP level, parallel liver function Pugh- Child classification, symptom score, functional status(Karnofsky score), and follow-up, statistical survival, application of SPSS19.0 software package for statistical analysis, combined with clinical data analysis.Result:1.Two after treatment, the clinical symptoms of the 1 groups were compared: the treatment group and control group were 79.2%, 45.2%, 87.5%, 54.5%,, two, and 0.018, respectively, 0.05 and 0.013, respectively. 2 Two the liver function and biochemical index of the 2 groups were compared: ALT and AST were significantly different from the control group(P < 0.01), and GGT treated group was significantly different from the control group(P < 0.05). 3.before and after treatment, the stability of the tumor was 58.3%, the stability of the control group was, and the stability of the control group was 45.5%, and there was no significant difference between the two groups(P=O.475). 4.the changes of AFP before and after treatment in two groups: no significant difference between the two groups before and after treatment(P > 0.05). 5.Two after treatment, the change of the card’s change:(CR+PR), in March, June, December, P value was less than two, 0.05 groups had statistical significance; in 18 months, 2 years and 2 years after P values were more than two, the 5 groups had no significant difference. Compared with CR+PR+NC, the value of P in March, June, December, 18 months after the first treatment was less than 0.05, and the P values were more than 2 years and 2 years after the first treatment.6.the average survival time and survival rate were compared: the average survival time of the treatment group and the control group were 10.17 and 13.67 months, respectively, and the control group was P=0.013 < 0.05. At the time of December, 18 months, 2 years and 2 years, there was no significant difference in the survival rate(P = 0.05). At the end of the experiment(June 2015), there were 3 cases of survival, while the control group had 1 cases at the end of the experiment. 7.safety detection: two groups of patients with non toxic side effects of the treatment of serum security, the two groups were not found adverse reactions and toxic side effects after treatment.Conclusion:The study showed that, compared with the control group, the treatment of primary liver cancer, from patients with symptom score, liver function biochemical indicators, AFP, Chi score, survival, and so on, in improving the clinical symptoms, improve the quality of life, prolong the survival period, has better effect, and its safety performance is good, non-toxic side effects. |
PDF Full Text Request